Momentum Stock Watch: Quest Diagnostics Incorporated (DGX)

Company Profile:

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated has a strategic collaboration with hc1. The company was founded in 1967 and is headquartered in Secaucus, New Jersey.

Recent News:

The company will report fourth quarter and full year 2019 results on Thursday, January 30, 2020, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

On Dec. 9, 2019, the company announced the pricing of a public offering of $800 million aggregate principal amount of its 2.950% senior notes due 2030 under the Quest Diagnostics’ shelf registration statement.

On Nov. 20, 2019, its Board of Directors declared a quarterly cash dividend of $0.53 per share, payable on January 29, 2020 to shareholders of record of Quest Diagnostics common stock on January 14, 2020.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



DGX’s strengths can be seen in its strong growth, strong profitability and better solvency compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, MACD is trying to cross back up and RSI stands at 55.86 with positive bias. We rate Quest Diagnostics Incorporated (DGX) a STRONG BUY.

About the Author

has written 14193 stories on this site.

Copyright © 2012 Nine Stocks